Hypertensive nephrosclerosis
HTN nephrosclerosis · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Chronic kidney damage from long-standing hypertension causing arteriolar and glomerular sclerosis, presenting as slowly progressive CKD with modest proteinuria and a bland sediment. Management centres on blood-pressure control and cardiovascular risk reduction.
Red flags
- Rapidly declining eGFR (suggests alternative diagnosis)
- Heavy/nephrotic-range proteinuria
- Active urinary sediment (casts, dysmorphic cells)
- Malignant hypertension with end-organ damage
- Asymmetric kidneys or renovascular features
Assessment
Differential diagnosis
- Hypertensive nephrosclerosis
- Diabetic kidney disease
- Primary glomerular disease (FSGS)
- Renovascular/ischaemic nephropathy
- Chronic tubulointerstitial disease
- APOL1-associated nephropathy
Investigations
- Blood pressure (clinic and out-of-office)
- eGFR trend and urine ACR (usually modest proteinuria)
- Urinalysis (bland sediment, no active casts)
- Renal ultrasound (symmetrically small, smooth kidneys in advanced disease)
- Exclude other causes (glucose, immunology where indicated)
- Assessment for end-organ damage (ECG/echo, retinal exam)
Management
- Establish the diagnosis clinically: long-standing hypertension, slowly progressive CKD, modest proteinuria and a bland urinary sediment
- Exclude mimics (diabetes, glomerulonephritis, renovascular disease) when the picture is atypical or proteinuria is heavy
- Set and achieve a blood-pressure target (generally <130/80, individualised)
- Use an ACE inhibitor or ARB first-line, especially with albuminuria
- Add calcium-channel blocker and/or diuretic (loop if eGFR <30) to reach target
- Reinforce lifestyle: sodium restriction, weight management, exercise, smoking cessation, alcohol moderation
- Consider an SGLT2 inhibitor for albuminuric CKD to slow progression
- Aggressively manage cardiovascular risk (statin, antiplatelet where indicated)
- Avoid nephrotoxins (NSAIDs) and review medications
- Monitor eGFR, ACR, potassium and BP regularly
- Investigate any acceleration in decline or new heavy proteinuria for an alternative diagnosis
- Refer to nephrology for rapid progression, diagnostic doubt or advanced CKD
Drugs & doses
Ramipril 2.5-10 mg PO daily OR losartan 50-100 mg PO daily
Amlodipine 5-10 mg PO once daily
Indapamide 2.5 mg PO daily (eGFR >30) or furosemide 20-80 mg PO daily (eGFR <30)
Dapagliflozin 10 mg PO once daily (albuminuric CKD)
Atorvastatin 20 mg PO once daily
Disposition
Primary care/CKD clinic with BP optimisation. Nephrology referral for rapid decline, heavy proteinuria or diagnostic uncertainty.
Complications & pitfalls
- Progressive CKD and end-stage kidney disease
- Cardiovascular events and left ventricular hypertrophy
- Hyperkalaemia from RAAS therapy
- Accelerated/malignant hypertension
- Retinopathy
Exam pearls
- It is a diagnosis of exclusion — heavy proteinuria or active sediment should prompt a search for another cause
- Bland sediment and modest proteinuria are typical
- BP control is the key intervention to slow progression
- Consider APOL1-associated nephropathy in patients of West African ancestry with apparent hypertensive CKD
- Small smooth symmetrical kidneys support chronicity
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.